Introduction
Barrett's esophagus develops when the normal lining of the lower esophagus is repeatedly damaged by stomach acid over years, and replaced by a different type of tissue more similar to the lining of the intestine — a process called intestinal metaplasia. It's a recognized complication of long-standing GERD, and its clinical significance lies in a small but real increased risk of progressing, through intermediate stages, toward esophageal adenocarcinoma. At KAGE, Barrett's esophagus is diagnosed on biopsy, graded for any dysplasia present, and managed with a surveillance and treatment plan matched to that grading — not treated as a single, uniform diagnosis.
How common is Barrett's esophagus, and how does esophageal cancer in India differ from the West?
An Indian study of GERD patients found suspicious columnar changes on endoscopy in around 16.5% of cases, with roughly 9% confirmed as true Barrett's esophagus (specialized intestinal metaplasia) on biopsy — and the presence of a hiatal hernia more than tripled that risk. This is an important number to know if you have long-standing reflux, since Barrett's usually causes no symptoms of its own. It's equally important to understand how esophageal cancer risk actually breaks down in India: in Western countries, Barrett's-related adenocarcinoma has now overtaken squamous cell carcinoma as the most common type of esophageal cancer, driven by rising GERD and obesity rates. In India, the picture is different — adenocarcinoma still accounts for only around 15–25% of esophageal cancers, while squamous cell carcinoma, linked primarily to tobacco and alcohol use rather than acid reflux, remains the majority. This doesn't make Barrett's surveillance any less important for those who have it — it does mean the two esophageal cancer risk stories in India are genuinely different, and worth understanding separately rather than assuming the Western narrative applies unchanged.
What increases the risk of Barrett's esophagus
- Long-standing, frequent GERD — the single strongest risk factor
- Hiatal hernia — associated with more than triple the risk in Indian GERD patients
- Obesity, particularly abdominal obesity
- Smoking
- Male sex and age over 50
- A family history of Barrett's esophagus or esophageal adenocarcinoma
Symptoms of Barrett's esophagus
Barrett's esophagus itself typically causes no distinct symptoms — people usually notice the symptoms of the underlying GERD (heartburn, regurgitation) rather than anything specific to the Barrett's changes. This is exactly why it's so often found incidentally during an endoscopy done to investigate reflux, rather than through symptoms prompting its discovery directly.
How Barrett's esophagus is diagnosed
- Upper GI endoscopy — the abnormal lining has a distinct appearance that can be identified visually
- Biopsy — required to confirm the diagnosis and check for dysplasia (precancerous cell changes), since the visual appearance alone isn't sufficient for a definitive diagnosis or grading
Dysplasia grading and surveillance: the staging that determines everything
Once confirmed, Barrett's esophagus is graded by whether dysplasia (precancerous cellular change) is present, and how advanced it is. This grading is what actually determines the monitoring schedule and whether treatment beyond surveillance is needed:
| Grade | What it means | Typical follow-up |
|---|---|---|
| No dysplasia | Barrett's changes present, no precancerous cell changes | Repeat endoscopy roughly every 3–5 years |
| Low-grade dysplasia | Early precancerous changes | Closer surveillance (6–12 months) or endoscopic treatment |
| High-grade dysplasia | Advanced precancerous changes | Endoscopic eradication therapy strongly recommended |
This is why the biopsy result — not just the diagnosis of ‘Barrett's esophagus’ as a label — is what should actually guide your next steps.
Barrett's esophagus treatment: matched to dysplasia grade
- For no dysplasia: strict acid suppression (usually PPIs) to control the reflux driving the changes, combined with surveillance endoscopy on schedule
- For low-grade dysplasia: either closer surveillance or endoscopic treatment, decided based on individual risk factors
- For high-grade dysplasia or early cancer confined to the lining: endoscopic eradication therapy, such as radiofrequency ablation (RFA) or endoscopic mucosal resection for any visible abnormal areas — highly effective at removing the affected tissue without surgery
- For more advanced disease: referral for further oncological evaluation and, in select cases, surgery
Barrett's esophagus care at KAGE
Barrett's esophagus is a consequence of untreated GERD, so care here addresses both: surveillance endoscopy with a proper biopsy protocol for the Barrett's segment itself, and definitive reflux control — medical, or endoscopic with ARMA or GERDx. Our gastroenterologists set the surveillance interval from your biopsy grade rather than a fixed calendar. If you have had reflux for years and have never been scoped, book a consultation.
Frequently asked questions
No — this is a common misconception based on Western data. In India, squamous cell carcinoma, linked to tobacco and alcohol rather than reflux, still accounts for the majority of esophageal cancers. Barrett's-related adenocarcinoma is a real but smaller share.
The tissue changes themselves don't typically reverse with medication alone, though controlling acid reflux can prevent further progression. Endoscopic treatments like radiofrequency ablation can remove affected tissue in cases with dysplasia.
It depends entirely on your dysplasia grade — roughly every 3–5 years with no dysplasia, much more frequently if any dysplasia is found. Your gastroenterologist will set the exact schedule based on your biopsy results.
It's an endoscopic procedure that uses controlled heat energy to remove the abnormal Barrett's tissue lining, allowing normal esophageal lining to regrow — performed without surgery, typically as an outpatient procedure.
Diagnostic endoscopy and biopsy are generally covered under standard health insurance; coverage for endoscopic ablation depends on your specific policy. Our team can help verify coverage during consultation.
It's possible, which is why ongoing surveillance continues even after successful endoscopic treatment — it isn't a one-time cure that eliminates future monitoring.
Barrett's esophagus can develop from long-standing acid exposure even when symptoms feel mild or well-controlled with medication, which is part of why endoscopic screening — not just symptom control — matters for long-standing GERD.
Not everyone, but screening is generally recommended for those with long-standing GERD plus other risk factors such as hiatal hernia, obesity, smoking history, or a family history of Barrett's or esophageal cancer — your gastroenterologist can assess whether it's right for you.
It's rare in children but can occur with long-standing, poorly controlled reflux; pediatric cases are evaluated by KAGE's pediatric gastroenterology team.
Book a consultation at KAGE
Speak to a KAGE gastroenterologist about your symptoms, your diagnosis, or a second opinion.